Search Orphan Drug Designations and Approvals
-
| Generic Name: | brigatinib | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Alunbrig | ||||||||||||||||
| Date Designated: | 04/28/2016 | ||||||||||||||||
| Orphan Designation: | Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC). | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Takeda Development Center Americas, Inc. 500 Kendall Street Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | brigatinib |
|---|---|---|
| Trade Name: | Alunbrig | |
| Marketing Approval Date: | 04/28/2017 | |
| Approved Labeled Indication: | Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib | |
| Exclusivity End Date: | 04/28/2024 | |
| Exclusivity Protected Indication* : | Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib | |
| 2 | Generic Name: | brigatinib |
|---|---|---|
| Trade Name: | Alunbrig | |
| Marketing Approval Date: | 05/22/2020 | |
| Approved Labeled Indication: | ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. | |
| Exclusivity End Date: | 05/22/2027 | |
| Exclusivity Protected Indication* : | For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib. | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







